The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer.
 
Michael S. May
No Relationships to Disclose
 
Margaux Wooster
No Relationships to Disclose
 
Benjamin May
No Relationships to Disclose
 
Catherine A. Shu
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Genentech/Roche; Gilead Sciences; Janssen; Takeda
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Janssen (Inst)
 
Brian S. Henick
Honoraria - DAVA Oncology; OncLive/MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; IDEAYA Biosciences; Jazz Pharmaceuticals; Regeneron; Sorrento Therapeutics
Research Funding - Genentech/Roche (Inst); Johnson & Johnson/Janssen (Inst); NexImmune (Inst); Stand Up 2 Cancer (Inst); V Foundation (Inst)
 
Mark Stoopler
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Stephanie Smith-Marrone
No Relationships to Disclose
 
Anjali Saqi
Honoraria - Dedham Group; Medscape
Consulting or Advisory Role - Abbvie; BMS; Boehringer Ingelheim; Genentech/Roche; Veracyte
Research Funding - Boehringer Ingelheim (Inst)
Patents, Royalties, Other Intellectual Property - Cell block patent (Inst)
 
Mahesh M. Mansukhani
Travel, Accommodations, Expenses - Bristol-Myers Squibb; E.R. Squibb Sons, LLC; Promega; Promega
 
Gregory J. Riely
Research Funding - Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Bayer; Merck
Other Relationship - Mirati Therapeutics; Pfizer; Roche/Genentech; Takeda
 
Dawn L. Hershman
Consulting or Advisory Role - AIM Specialty Health
 
Benjamin Herzberg
Honoraria - Boxer Capital; Eisai; OncLive/MJH Life Sciences
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; IDEAYA Biosciences (Inst); Monte Rosa Therapeutics (Inst); Prelude Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst)